STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Clinical trials for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a new drug combo shrink tough lung tumors?
Disease control OngoingThis study tests whether adding the drug veliparib to standard chemotherapy and radiation helps people with stage III lung cancer that can't be removed by surgery. About 53 adults took part to find the best dose and see if the combination slows cancer growth. The goal is to impro…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:25 UTC
-
New combo tackles Drug-Resistant lung cancer
Disease control OngoingThis early-stage trial tests a combination of two drugs, sapanisertib and osimertinib, in people with advanced EGFR-mutant non-small cell lung cancer that has worsened after previous treatment. The main goal is to find the safest dose and check for side effects. About 36 particip…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 05:07 UTC
-
New cocktail for inoperable lung cancer shows promise in early trial
Disease control OngoingThis study tested a three-part treatment for people with stage III lung cancer that cannot be removed by surgery. The treatment combined standard chemotherapy (cisplatin and etoposide) with radiation, followed by two additional drugs (docetaxel and bevacizumab) to try to kill mor…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
Targeted pill after surgery may extend life for lung cancer patients
Disease control OngoingThis study tests whether taking erlotinib (a targeted therapy pill) after surgery helps people with a specific type of lung cancer (EGFR-mutant) live longer compared to just watching and waiting. About 390 patients with early-stage lung cancer that was fully removed took part. Th…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of two drugs, cediranib and olaparib, in people with advanced or inoperable solid tumors, including certain breast, lung, and pancreatic cancers. The goal is to see if the combo can shrink tumors or slow their growth by blocking enzymes that cancer …
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
Lung cancer study aims to match patients with precision treatments
Knowledge-focused OngoingThis study screens people with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. By analyzing the genes in their tumor tissue, doctors hope to identify which patients might benefit from specific targeted therapies. The goal is to better persona…
Matched conditions: STAGE IIIA LUNG NON-SMALL CELL CANCER AJCC V7
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 17, 2026 05:22 UTC